论文部分内容阅读
目的探讨华法林在非瓣膜病心房颤动(房颤)并发脑栓塞患者中的应用现状。方法回顾性分析145例非瓣膜病房颤患者临床资料。结果在非瓣膜病房颤并发脑栓塞的患者中,华法林作为预防用药和治疗用药使用率只有13.8%和51.7%。华法林预防用药仅与年龄存在相关关系(P<0.01);而住院期间的用药则与CHA2DS2-VASc评分、糖尿病和动脉硬化密切相关(r=0.000、0.009和0.005,P<0.01)。结论华法林可降低非瓣膜病房颤缺血性脑卒中的发生率,但存在低使用率的现状,临床上应予以重视和推广使用。
Objective To investigate the application of warfarin in patients with nonvalvular atrial fibrillation (AF) complicated with cerebral embolism. Methods A retrospective analysis of 145 cases of non-valvular atrial fibrillation in patients with clinical data. Results In patients with non-valvular atrial fibrillation and cerebral embolism, warfarin was used as a prophylactic and therapeutic drug with only 13.8% and 51.7%, respectively. Warfarin prophylaxis was only related to age (P <0.01), while medication during hospitalization was closely related to CHA2DS2-VASc score, diabetes and arteriosclerosis (r = 0.000, 0.009 and 0.005, P <0.01). Conclusion Warfarin can reduce the incidence of atrial fibrillation ischemic stroke in patients with non-valvular disease, but there is a low utilization rate of the status quo, which should be taken seriously and popularized.